<DOC>
	<DOCNO>NCT02169765</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) third lead death cancer world . It important explore safe effective therapy early-stage HCC . Previous study report radiofrequency ablation ( RFA ) high efficacy associate few complication short hospital stay hepatic resection ( HR ) early-stage HCC . However , meta-analysis systematic review find RFA associate high recurrence rate lower long-term overall survival .</brief_summary>
	<brief_title>HR Versus RFA Early Stage HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Age 1875 year Clinical diagnosis HCC confirm histopathological examination surgical sample patient Tumor stage fit Milan Criteria Patients ChildPugh A liver function No previous neoadjuvant treatment No evidence metastasis lymph node and/or distant metastasis basis preoperative imaging result perioperative finding No malignancy HCC 5 year prior initial HCC treatment No history encephalopathy , ascites refractory diuretic variceal bleed History cardiac disease : Congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 ; active coronary artery disease ( myocardial infarction 6 month prior study entry permit ) ; Cardiac arrhythmia require antiarrhythmic therapy beta blocker , calcium channel blocker digoxin ; Uncontrolled hypertension ( failure diastolic blood pressure fall 90 mmHg , despite use 3 antihypertensive drug ) . Active clinically serious infection ( &gt; grade 2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events version 3.0 ) Known history human immunodeficiency virus ( HIV ) infection Known Central Nervous System tumor include metastatic brain disease Patients clinically significant gastrointestinal bleeding within 30 day prior study entry History organ allograft Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Any condition unstable could jeopardize safety patient his/her compliance study Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within seven day prior start study drug . Both men woman enrol trial must use adequate barrier birth control measure course trial . Excluded therapy medication , previous concomitant : Autologous bone marrow transplant stem cell rescue within four month start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Liver Cancer</keyword>
</DOC>